<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Merrimack Pharma Grabs $60M Upfront From Sanofi for Cancer Antibody</title>
	<atom:link href="http://www.xconomy.com/boston/2009/10/01/merrimack-pharma-grabs-60m-upfront-from-sanofi-for-cancer-antibody/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.xconomy.com/boston/2009/10/01/merrimack-pharma-grabs-60m-upfront-from-sanofi-for-cancer-antibody/</link>
	<description>Business + Technology in the Exponential Economy</description>
	<lastBuildDate>Sat, 11 Feb 2012 03:54:18 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.4</generator>
	<item>
		<title>By: Merrimack pharmaceutical &#124; Goldencove</title>
		<link>http://www.xconomy.com/boston/2009/10/01/merrimack-pharma-grabs-60m-upfront-from-sanofi-for-cancer-antibody/comment-page-1/#comment-412852</link>
		<dc:creator>Merrimack pharmaceutical &#124; Goldencove</dc:creator>
		<pubDate>Sat, 28 May 2011 21:45:49 +0000</pubDate>
		<guid isPermaLink="false">http://www.xconomy.com/?p=44111#comment-412852</guid>
		<description>[...] Merrimack Pharma Grabs $60M Upfront From Sanofi for Cancer Antibody &#124;Cambridge, MA-based Merrimack Pharmaceuticals struck a big deal today with Paris-based pharmaceutical giant Sanofi-Aventis that will bring $60 million in &#8230; Merrimack also retained rights to co-promote the drug, MM-121, in the U.S., the world&#8217;s biggest pharmaceutical market. [...]</description>
		<content:encoded><![CDATA[<p>[...] Merrimack Pharma Grabs $60M Upfront From Sanofi for Cancer Antibody |Cambridge, MA-based Merrimack Pharmaceuticals struck a big deal today with Paris-based pharmaceutical giant Sanofi-Aventis that will bring $60 million in … Merrimack also retained rights to co-promote the drug, MM-121, in the U.S., the world’s biggest pharmaceutical market. [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>

